Ray Dalio's HAE Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 59.1K shares of Haemonetics Corporation (HAE) worth $2.88 M, representing 0.01% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 18 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in HAE, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 24.8K shares. Largest reduction occurred in Q3 2024, reducing 35.7K shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Haemonetics Corporation (HAE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Haemonetics Corporation (HAE) Trades by Ray Dalio
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2021 | +51,905 | New Buy | 51,905 | $66.64 |
| Q3 2021 | -4,236 | Reduce 8.16% | 47,669 | $70.59 |
| Q4 2021 | +8,306 | Add 17.42% | 55,975 | $53.04 |
| Q1 2022 | +17,518 | Add 31.30% | 73,493 | $63.22 |
| Q2 2022 | +7,552 | Add 10.28% | 81,045 | $65.19 |
| Q3 2022 | -64 | Reduce 0.08% | 80,981 | $74.03 |
| Q4 2022 | -21,454 | Reduce 26.49% | 59,527 | $78.65 |
| Q1 2023 | +2,102 | Add 3.53% | 61,629 | $82.75 |
| Q2 2023 | -6,434 | Reduce 10.44% | 55,195 | $85.14 |
| Q3 2023 | +4,957 | Add 8.98% | 60,152 | $89.58 |
| Q4 2023 | -5,413 | Reduce 9.00% | 54,739 | $85.51 |
| Q1 2024 | -7,960 | Reduce 14.54% | 46,779 | $85.35 |
| Q2 2024 | -3,206 | Reduce 6.85% | 43,573 | $82.73 |
| Q3 2024 | -35,747 | Reduce 82.04% | 7,826 | $80.38 |
| Q4 2024 | -2,434 | Reduce 31.10% | 5,392 | $78.08 |
| Q1 2025 | +16,128 | Add 299.11% | 21,520 | $63.55 |
| Q2 2025 | +24,764 | Add 115.07% | 46,284 | $74.61 |
| Q3 2025 | +12,820 | Add 27.70% | 59,104 | $48.74 |
Ray Dalio's Haemonetics Corporation Investment FAQs
Ray Dalio first purchased Haemonetics Corporation (HAE) in Q2 2021, acquiring 51,905 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Haemonetics Corporation (HAE) for 18 quarters since Q2 2021. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's largest addition to Haemonetics Corporation (HAE) was in Q2 2021, adding 51,905 shares worth $3.46 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 59,104 shares of Haemonetics Corporation (HAE), valued at approximately $2.88 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Haemonetics Corporation (HAE) represents approximately 0.01% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's peak holding in Haemonetics Corporation (HAE) was 81,045 shares, as reported at the end of Q2 2022. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.